Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,041.53 +23.14 (+0.46%) Dow
38,084.97 +181.68 (+0.48%) Nasdaq
15,750.09 +144.61 (+0.93%) Bitcoin USD
59,241.52 +2,448.70 (+4.31%) CMC Crypto 200
1,278.74 +8.00 (+0.63%)
Longeveron Inc. (LGVN)
| Previous close | 1.7400 |
| Open | 1.7800 |
| Bid | 1.6700 x 100 |
| Ask | 1.7700 x 200 |
| Day's range | 1.7000 - 1.7850 |
| 52-week range | 1.6000 - 44.0000 |
| Volume | |
| Avg. volume | 2,142,776 |
| Market cap | 8.469M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 5:00 p.m. ET. Conference Call Details: Conference Call Number: 1.877.407.0789 Conference ID: 13745868 Call meTM Featur
- GlobeNewswire
Longeveron to Present at the Planet MicroCap Showcase
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024. Details for the Company’s presentation: Date:Wednesday, May 1, 2024 Time:4:30 p.m. PT Webcast:Click Here An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference. If
- GlobeNewswire
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock havin
